Vanguard Personalized Indexing Management LLC Acquires 4,302 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Alnylam Pharmaceuticals by 47.3%, acquiring an additional 4,302 shares worth approximately $4.37 million in the most recent quarter.
• Institutional investors collectively hold 92.97% of Alnylam’s stock, reflecting significant interest from various funds, including Bessemer Group Inc. and GAMMA Investing LLC.
• Multiple research firms have raised their target prices for Alnylam Pharmaceuticals, with Royal Bank of Canada setting a new target at $500.00 and Evercore ISI increasing theirs to $515.05, indicating strong market confidence.

Vanguard Personalized Indexing Management LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 47.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,390 shares of the biopharmaceutical company's stock after buying an additional 4,302 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Alnylam Pharmaceuticals were worth $4,368,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth $275,000. Strs Ohio bought a new position in Alnylam Pharmaceuticals in the first quarter valued at about $7,781,000. GAMMA Investing LLC raised its position in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after purchasing an additional 77 shares during the last quarter. Finally, Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $243,000. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,405 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the sale, the executive vice president owned 27,438 shares of the company's stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,129,377.08. This represents a 13.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock valued at $44,160,261 over the last ninety days. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ALNY. Royal Bank Of Canada increased their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an "outperform" rating in a research report on Friday, September 19th. Evercore ISI increased their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research report on Thursday, September 11th. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Finally, Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price for the company in a research report on Monday, August 4th. Twenty-four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $457.08.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of ALNY stock opened at $469.36 on Wednesday. The stock has a market cap of $61.52 billion, a price-to-earnings ratio of -190.02 and a beta of 0.36. The stock has a 50-day moving average of $453.28 and a 200-day moving average of $348.35. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.